Lifeboat Foundation

Dinorah Delfin has unleashed another exceptional edition of Immortalist Magazine. One of the best aspects is the dueling articles on the future states of Artificial General Intelligence (AGI).

Daniel Faggella constructs another dismal, dreary, depressing, destruction of hope for a benevolent artificial general intelligence. Emphasis on depressing. He has a wonderful way of creating a series of logical roadblocks to any optimism that there is a future with a compassionate artificial general intelligence. But he seems to be arguing against a contention that probably nobody believes in. He is arguing that there is no certainty that an artificial general intelligence will be benevolent. Most thinking humanoids are going to agree with that perspective. As he points out forcefully in his concluding and strongest rebuttal: no one knows what the future holds.

But no one is looking for absolute certainty in the far future. Transhumanists in general are looking for a path forward to an existence full of superhappiness, superintelligence and superlongevity.

Multiple lines of evidence show that the anti-aging and cognition-enhancing protein Klotho fosters neuronal survival, increases the anti-oxidative stress defense, and promotes remyelination of demyelinated axons. Thus, upregulation of the Klotho gene can potentially alleviate the symptoms and/or prevent the progression of age-associated neurodegenerative diseases such as Alzheimer’s disease and demyelinating diseases such as multiple sclerosis. Here we used a CRISPR-dCas9 complex to investigate single-guide RNA (sgRNA) targeting the Klotho promoter region for efficient transcriptional activation of the Klotho gene. We tested the sgRNAs within the — 1 to — 300 bp of the Klotho promoter region and identified two sgRNAs that can effectively enhance Klotho gene transcription. We examined the transcriptional activation of the Klotho gene using three different systems: a Firefly luciferase (FLuc) and NanoLuc luciferase (NLuc) coincidence reporter system, a NLuc knock-in in Klotho 3’-UTR using CRISPR genomic editing, and two human cell lines: neuronal SY5Y cells and kidney HK-2 cells that express Klotho endogenously. The two sgRNAs enhanced Klotho expression at both the gene and protein levels. Our results show the feasibility of gene therapy for targeting Klotho using CRISPR technology. Enhancing Klotho levels has a therapeutic potential for increasing cognition and treating age-associated neurodegenerative, demyelinating and other diseases, such as chronic kidney disease and cancer.

Keywords: Alzheimer’s disease; Cancer; Chronic kidney disease; Multiple sclerosis; Myelin; Neuroprotection.

Circa 2019

Memory loss is usually seen as an inevitable part of ageing. But new research suggests that magnetic pulse stimulation can help older brains recover a little of their youthful vitality.

The mission of healthy life extension, or healthy longevity promotion, raises a broad variety of questions and tasks, relating to science and technology, individual and communal ethics, and public policy, especially health and science policy. Despite the wide variety, the related questions may be classified into three groups. The first group of questions concerns the feasibility of the accomplishment of life extension. Is it theoretically and technologically possible? What are our grounds for optimism? What are the means to ensure that the life extension will be healthy life extension? The second group concerns the desirability of the accomplishment of life extension for the individual and the society, provided it will become some day possible through scientific intervention.

How will then life extension affect the perception of personhood? How will it affect the availability of resources for the population? Yet, the third and final group can be termed normative. What actions should we take? Assuming that life extension is scientifically possible and socially desirable, and that its implications are either demonstrably positive or, in case of a negative forecast, they are amenable – what practical implications should these determinations have for public policy, in particular health policy and research policy, in a democratic society? Should we pursue the goal of life extension? If yes, then how? How can we make it an individual and social priority? Given the rapid population aging and the increasing incidence and burden of age-related diseases, on the pessimistic side, and the rapid development of medical technologies, on the optimistic side, these become vital questions of social responsibility. And indeed, these questions are often asked by almost any person thinking about the possibility of human life extension, its meaning for oneself, for the people in one’s close circle, for the entire global community. Many of these questions are rather standard, and the answers to them are also often quite standard. Below some of those frequently asked questions and frequently given answers are given, with specific reference to the possibility and desirability of healthy human life extension, and the normative actions that can be undertaken, by the individual and the society, to achieve this goal.

Continue reading “Frequently Asked Questions on the Ethics of Lifespan and Healthspan Extension” »

The authors draw attention to several randomized clinical studies in humans that have found that over the counter supplements such as n-acetylcysteine (NAC), which is used to treat acetaminophen poisoning and is also used as a mucus thinner to help reduce bronchitis exacerbations, and elderberry extracts, have evidence for shortening the duration of influenza by about two to four days and reducing the severity of the infection. The authors also note several nutraceuticals such as spirulina, beta-glucan, glucosamine, and NAC have either been found to reduce the severity of infection or to cut the rate of death in half in animals infected with influenza. Furthermore, one clinical study in humans testing spirulina noted significant reductions in viral load in those infected with HIV.

In a compelling article in Progress in Cardiovascular Diseases, published by Elsevier, Mark McCarty of the Catalytic Longevity Foundation, San Diego, CA, USA, and James DiNicolantonio, PharmD, a cardiovascular research scientist at Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA, propose that certain nutraceuticals may help provide relief to people infected with encapsulated RNA viruses such as influenza and coronavirus.

In the United States, influenza infects around 30 million people every year causing around 30,000 deaths. While there are medications approved for the treatment of influenza, they typically are costly, have side effects, and are not very effective. Additionally, vaccinations against influenza may only be effective in around 50 percent of those vaccinated. Thus, there is a need for safer and effective alternatives in those infected with influenza.

Over the past few months, a novel RNA coronavirus, now called COVID-19, has broken out in China and has spread to over two dozen countries and infected more than 76,000 people causing more than 2,000 deaths. This novel coronavirus is much more lethal than the typical flu, with a current mortality rate of about 2.92 percent. In other words, around 1 in 33 people who are infected with this novel coronavirus will die. Whereas the annual flu has a mortality rate of just 0.05 to 0.1 percent. This means that around 1 in 1,000 to 2,000 people infected with the annual flu will die. In other words, COVID-19 is around 30 to 60 times more lethal than the typical annual flu.

Continue reading “Recent research points the way toward a practical nutraceutical strategy for coping with RNA virus infections including influenza and coronavirus” »

Because of the central importance of tissue repair to all organisms, Neves assumed that many of the mechanisms behind it would be shared among all animals. So she started looking at proteins produced by immune cells in the well-known animal model of the fruit fly.

She discovered that a poorly-understood protein known as MANF (mesencephalic astrocyte-derived neurotrophic factor) plays a crucial role in reducing inflammation in fruit flies. More importantly, she found that mice and humans also produce it, and its prevalence reduces in all the species as they age, suggesting it plays a key role in limiting age-related inflammation.

That prompted her to see if introducing MANF would boost the effectiveness of stem cell treatments in older animals. She used the protein in combination with a procedure that uses stem cells to replace degenerating photoreceptors in the retina of older mice and found it greatly improved the restoration of vision.

I interviewed transhumanist thinker Anders Sandberg, research fellow at Oxford Universities Future of Humanity Institute. We discuss how the global transhumanist movement has changed, the potential political impact of technological revolutions and the debate around cryonics. Fairly new channel so very grateful for any subscribers smile

My interview with Anders Sandberg, a prominent transhumanist thinker and research fellow at the Future of Humanity Institute at Oxford University.

Continue reading “A Transhumanism future? — Anders Sandberg interview” »

Senolitics can be one of the first for one of the causes of ageing. One of the agents that have shown a senolytic effect is fisetin.

Because of the availability and safety of fisetin, we decided to conduct our experiments of this drug in a person with autoimmune thyroiditis. It is noteworthy that, unlike most trials, we focus not on chronic inflammation but on immune function.

For this test, we need your financial help.

Continue reading “Clinical trials of Fisetin in a person with autoimmune thyroiditis” »

March 9 (UPI) — Scientists have developed a technique for repairing damaged DNA. The breakthrough, published this week in the journal Nature Communications, could pave the way for new therapies for cancer and neurodegenerative disorders.

The accumulation of DNA damage is responsible for aging, cancer and neurological diseases like motor neuron disease, also known as ALS.

Until now, scientists have struggled to find ways to repair this kind of damage. However, researchers have discovered a new protein called TEX264 that can combine with other enzymes to find and destroy toxic proteins that bind to DNA and trigger damage.